GILEAD SCIENCES, INC.

Organization · CA
Hires government relations

Client is a biopharmaceutical company that develops medicines in areas of unmet need.

Who they hire

2024 · 2 filings · Health Issues, Medicare/Medicaid
$██,███ / qtrUnlock

What they lobby on

Access and reimbursement of drugs in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 H.R.5378 - Lower Costs, More Transparency Act Issues related to Part D delinking of PBMs in H.R.2880 - Protecting Patients Against PBM Abuses Act, S.1967 - PBM Act, S. 2973 - The Modernizing and Ensuring PBM Accountability (MEPA) Act, H.R.8261 - Preserving Telehealth, Hospital, and Ambulance Access Act S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 H.R.5547/S. 476- MINI Act S.2764/H.R.5391 - Protecting Patient Access to Cancer and Complex Therapies Act of 2023 S.3131 - ORPHAN Cures Act, H.R.5539 - Optimizing Research Progress Hope and New Cures Act
Medicare/Medicaid · 2024 Q2
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to commercial delinking of PBMs - H.R.6283/S.1542 - DRUG Act
Health Issues · 2024 Q2
Access and reimbursement of drugs in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 H.R.5378 - Lower Costs, More Transparency Act Issues related to Part D delinking of PBMs, H.R.2880 - Protecting Patients Against PBM Abuses Act, S.1967 - PBM Act S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
Medicare/Medicaid · 2024 Q1
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. H.R.5378 - Lower Costs, More Transparency Act Issues related to commercial delinking of PBMs - H.R.6283/S.1542 - DRUG Act
Health Issues · 2024 Q1